| PUBLICATION DETAILS |
Publication Date
July 2003
|
I.S.B.N. (print)
0-478-27905-1 |
|
|
|
| DEVELOPED BY |
Accident Compensation Corporation (ACC)
Shamrock House
81-83 Molesworth St
PO Box 242
Wellington
New Zealand
Phone: 04 918 7700
Fax: 04 918 7701
E-mail: information@acc.co.nz |
|
|
|
| ENDORSED BY |
|
| REQUIRED TOOLS |
Documents are in PDF format. You'll need the FREE Adobe Acrobat Reader to browse and print them.
|
|
|
| Diagnosis and Management of Soft Tissue Knee Injuries: Internal Derangements |
| On September 30, 2004, Vioxx (rofecoxib) was withdrawn from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events. See the U.S. Food and Drug Administration (FDA) Web site for more information. Subsequently, on December 23, 2004, the FDA issued a public health advisory concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs) including the COX-2 selective agents Celebrex (celecoxib), Bextra (valdecoxib) and a non-selective NSAID, naproxen (sold as Aleve, Naprosyn and other trade name and generic products). See the FDA web site for more information . |
|
